- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00703911
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (ONE)
2016년 11월 22일 업데이트: Novo Nordisk A/S
A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors
This study was conducted in Africa, Europe, the Middle-East and South America.
The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
연구 개요
연구 유형
관찰
등록 (실제)
102
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Sandton, 남아프리카, 2146
- Novo Nordisk Investigational Site
-
-
-
-
-
Alphen a/d Rijn, 네덜란드
- Novo Nordisk Investigational Site
-
-
-
-
-
Mainz, 독일, 55127
- Novo Nordisk Investigational Site
-
-
-
-
-
Caracas, 베네수엘라
- Novo Nordisk Investigational Site
-
-
-
-
-
Brussels, 벨기에, 1070
- Novo Nordisk Investigational Site
-
-
-
-
-
Riyadh, 사우디 아라비아, 3542
- Novo Nordisk Investigational Site
-
-
-
-
-
Malmö, 스웨덴, 202 15
- Novo Nordisk Investigational Site
-
-
-
-
-
Algiers, 알제리, 16035
- Novo Nordisk Investigational Site
-
-
-
-
-
Crawley, 영국, RH11 9RT
- Novo Nordisk Investigational Site
-
-
-
-
-
Vienna, 오스트리아, A-1010
- Novo Nordisk Investigational Site
-
-
-
-
-
Rome, 이탈리아, 00144
- Novo Nordisk Investigational Site
-
-
-
-
-
Prague, 체코 공화국, 16000
- Novo Nordisk Investigational Site
-
-
-
-
-
Istanbul, 칠면조, 34335
- Novo Nordisk Investigational Site
-
-
-
-
-
Paco de Arcos, 포르투갈, 2780-730
- Novo Nordisk Investigational Site
-
-
-
-
-
Warszawa, 폴란드, PL-02-274
- Novo Nordisk Investigational Site
-
-
-
-
-
Paris La défense cedex, 프랑스, 92932
- Novo Nordisk Investigational Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
남성
샘플링 방법
비확률 샘플
연구 인구
Patients with haemophilia A or B with inhibitors, using activated recombinant human factor VII as on-demand treatment
설명
Inclusion Criteria:
- Diagnosed with haemophilia A or B with inhibitors
- Experience mild to moderate spontaneous bleeds which require on-demand treatment and who are currently prescribed activated recombinant human factor VII
- Be able and willing to provide informed consent (or proxy consent by caregiver, if applicable), as required by local research ethics committee, governmental or regulatory authorities
- Be willing to provide information on at least one alternate contact person in the event that the patient be somehow lost-to-follow-up over the course of registry participation (not applicable if patient is withdrawn)
Exclusion Criteria:
- Known hypersensitivity to the active substance or the excipients in the formulation of activated recombinant human factor VII, or to mouse, hamster or bovine protein
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
activated recombinant human factor VII
Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
|
Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes)
기간: within 9 hours of first injection
|
The percentage of bleed treatments successfully resulting in bleed resolution.
Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of "Effective" considered as successful treatment.
|
within 9 hours of first injection
|
Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes)
기간: within 9 hours of first injection
|
The percentage of bleed treatments successfully resulting in bleed resolution.
Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of "Effective" considered as successful treatment.
|
within 9 hours of first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes)
기간: within 9 hours of first injection
|
The percentage of participants with effective pain relief.
Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.
|
within 9 hours of first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes)
기간: within 9 hours of first injection
|
The percentage of participants with effective pain relief.
Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.
|
within 9 hours of first injection
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes)
기간: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective haemostasis at 3 different time points for all bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes)
기간: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective haemostasis at 3 different time points for all bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes)
기간: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective pain relief at 3 different time points for all bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes)
기간: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective pain relief at 3 different time points for spontaneous bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Total Number of Injections (All Bleed Episodes)
기간: individual bleed episode
|
The median number of injections required to treat individual bleed episodes.
|
individual bleed episode
|
Total Number of Injections (Spontaneous Bleed Episodes)
기간: individual bleed episode
|
The median number of injections required to treat individual bleed episodes.
|
individual bleed episode
|
Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes)
기간: individual bleed episode
|
The median total cumulative dose required to treat individual bleed episodes.
|
individual bleed episode
|
Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes)
기간: individual bleed episode
|
The median total cumulative dose required to treat individual bleed episodes.
|
individual bleed episode
|
Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes)
기간: duration of bleed episode
|
Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely satisfied to extremely dissatisfied.
The percentage of bleed episodes for which patients reported "extremely satisfied", "very satisfied" or "satisfied" is presented.
|
duration of bleed episode
|
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes)
기간: duration of bleed episode
|
Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely satisfied to extremely dissatisfied.
The percentage of bleed episodes for which patients reported "extremely satisfied", "very satisfied" or "satisfied" is presented.
|
duration of bleed episode
|
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes)
기간: duration of bleed episode
|
Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely difficult to extremely easy.
The percentage of bleed episodes for which patients reported "extremely easy", "very easy" or "easy" is presented.
|
duration of bleed episode
|
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes)
기간: duration of bleed episode
|
Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely difficult to extremely easy.
The percentage of bleed episodes for which patients reported "extremely easy", "very easy" or "easy" is presented.
|
duration of bleed episode
|
Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes)
기간: duration of bleed episode
|
Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods.
If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable
|
duration of bleed episode
|
Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes)
기간: duration of bleed episode
|
Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods.
If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable
|
duration of bleed episode
|
Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes)
기간: duration of bleed episode
|
Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods.
If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable.
|
duration of bleed episode
|
Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score
기간: Baseline (week 0) and and registry discontinuation (up to 28 months)
|
The Haemo-QoL is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia.
Scores are reported on a 0 to 100 scale-higher scores indicate more impairment.
|
Baseline (week 0) and and registry discontinuation (up to 28 months)
|
Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score
기간: Baseline (week 0) and and registry discontinuation (up to 28 months)
|
The adult Haemo-QoL-A is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia.
Scores are reported on a 0 to 100 scale-higher scores indicate more impairment.
|
Baseline (week 0) and and registry discontinuation (up to 28 months)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (All Bleed Episodes)
기간: within 9 hours after first injection
|
Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "effective" = bleed resolved or substantially improved; "partially effective" = bleed with some improvement; "ineffective" = bleed with no change or with worsening.
|
within 9 hours after first injection
|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (Spontaneous Bleed Episodes)
기간: within 9 hours after first injection
|
Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "effective" = bleed resolved or substantially improved; "partially effective" = bleed with some improvement; "ineffective" = bleed with no change or with worsening.
|
within 9 hours after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (All Bleed Episodes)
기간: within 9 hours after first injection
|
Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "Better" = pain resolved or decreased substantially; "Same" = no change; "Worsened" = pain worsening.
|
within 9 hours after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (Spontaneous Bleed Episodes)
기간: within 9 hours after first injection
|
Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "Better" = pain resolved or decreased substantially; "Same" = no change; "Worsened" = pain worsening.
|
within 9 hours after first injection
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2008년 3월 1일
기본 완료 (실제)
2010년 7월 1일
연구 완료 (실제)
2010년 7월 1일
연구 등록 날짜
최초 제출
2008년 6월 19일
QC 기준을 충족하는 최초 제출
2008년 6월 23일
처음 게시됨 (추정)
2008년 6월 24일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2017년 1월 11일
QC 기준을 충족하는 마지막 업데이트 제출
2016년 11월 22일
마지막으로 확인됨
2016년 11월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
eptacog alfa (activated)에 대한 임상 시험
-
CSL Behring완전한
-
IRCCS Policlinico S. Matteo완전한
-
AryoGen Pharmed Co.완전한
-
Novo Nordisk A/S완전한선천성 출혈 장애 | 억제제가 있는 혈우병 A | 억제제가 있는 혈우병 B미국
-
Vanderbilt University Medical CenterNational Center for Research Resources (NCRR); Vanderbilt Kennedy Center완전한
-
AryoGen Pharmed Co.완전한
-
Novo Nordisk A/S완전한후천성 출혈 장애 | 뇌내출혈미국, 스페인, 독일, 스웨덴, 네덜란드, 오스트리아, 벨기에, 싱가포르, 대만, 이스라엘, 이탈리아, 덴마크, 호주, 태국, 프랑스, 노르웨이, 크로아티아, 홍콩, 중국, 캐나다, 스위스, 브라질, 핀란드
-
Novo Nordisk A/S완전한선천성 출혈 장애 | 혈우병 A | 혈우병 B미국, 스페인, 대만, 칠면조, 폴란드, 크로아티아, 이탈리아, 말레이시아, 브라질, 영국, 헝가리, 이스라엘, 태국, 일본, 남아프리카, 캐나다, 프랑스, 아르헨티나